MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial

  • Etude concernée: IFCT-1701
  • Auteurs / Authors: Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA
  • Journal / Conference: Journal of Thoracic Oncology
  • Année / Year: 2025
  • PMID: 36841541
  • Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/36841541/
  • PDF: 1-s2.0-S1936523325002517-main.pdf